Anti-TM4SF1-chimeric antigen receptor T cell therapy (Shanghai Biomed-Union Biotechnology)

N/A

Report date: 2024/01/02 14:31:31

Base Information

Drug NameAnti-TM4SF1-chimeric antigen receptor T cell therapy (Shanghai Biomed-Union Biotechnology)

Drug Alias NameCART-TM4SF1 cells (Shanghai Biomed-Union Biotechnology)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Transmembrane 4 L6 family member 1

TargetsTransmembrane 4 L6 family member 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesShanghai Biomed-Union Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Biomed-Union Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A